Cargando…

Cardiometabolic Complications after Androgen Deprivation Therapy in a Man with Prostate Cancer: Effects of 3 Years Intermittent Testosterone Supplementation

Androgen deprivation therapy (ADT) for prostate carcinoma (PCa) may cause cardiometabolic complications unless intermittent androgen blockade (IAB) is instituted. An 80-year-old caucasian man was diagnosed intermediate grade (Gleason 4 + 3) PCa and was treated with continuous ADT with triptorelin pl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aversa, Antonio, Francomano, Davide, Lenzi, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2012
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355839/ https://www.ncbi.nlm.nih.gov/pubmed/22645517 http://dx.doi.org/10.3389/fendo.2012.00017

Ejemplares similares

Effects of Five-Year Treatment with Testosterone Undecanoate on Metabolic and Hormonal Parameters in Ageing Men with Metabolic Syndrome
por: Francomano, Davide, et al.
Publicado: (2014)

Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer
por: Qin, Caipeng, et al.
Publicado: (2022)

Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
por: Caramella, Irene, et al.
Publicado: (2022)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Assessment of oligometastasis status of prostate cancer following combined robot-assisted radical prostatectomy and androgen deprivation versus androgen deprivation therapy alone using PSA percentage decline rate
por: Li, Xuwen, et al.
Publicado: (2023)

Benefits of intermittent/continuous androgen deprivation in patients with advanced prostate cancer
por: MURESANU, HORIA
Publicado: (2016)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
por: Abrahamsson, Per-Anders
Publicado: (2017)

Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Prostate Cancer
por: Delgado, Jessica, et al.
Publicado: (2022)

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis
por: Chen, Jiuzhou, et al.
Publicado: (2023)

Acute endothelial response to testosterone gel administration in men with severe hypogonadism and its relationship to androgen receptor polymorphism: a pilot study
por: Francomano, D., et al.
Publicado: (2015)

Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer
por: Nam, Wook, et al.
Publicado: (2018)

Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation
por: Brady-Nicholls, Renee, et al.
Publicado: (2020)

Unrecognized Kinetics of Serum Testosterone: Impact on Short-Term Androgen Deprivation Therapy for Prostate Cancer
por: Koo, Kyo Chul, et al.
Publicado: (2014)

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
por: Akitake, Naoko, et al.
Publicado: (2018)

A Novel Liver-targeted Testosterone Therapy for Sarcopenia in Androgen Deprived Men With Prostate Cancer
por: Rhee, Handoo, et al.
Publicado: (2021)

Testosterone Recovery after Androgen Deprivation Therapy in Prostate Cancer: Building a Predictive Model
por: Borque-Fernando, Ángel, et al.
Publicado: (2023)

Testosterone Promotes Glioblastoma Cell Proliferation, Migration, and Invasion Through Androgen Receptor Activation
por: Rodríguez-Lozano, Dulce Carolina, et al.
Publicado: (2019)

SAT-045 Free Testosterone and Cardiometabolic Parameters in Adult Men - Comparison of Algorithms for Calculation of Serum Free Testosterone
por: Holmboe, Stine Agergaard, et al.
Publicado: (2020)

Cardiometabolic and Skeletal Risk Factors in Black Men with Prostate Cancer Starting Androgen Deprivation Therapy
por: Gunnarsson, Orvar, et al.
Publicado: (2015)

Three cases of nonmetastatic prostate cancer treated successfully with primary intermittent androgen deprivation therapy over 10 years
por: Shida, Yohei, et al.
Publicado: (2017)

Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer—time for a rethink?
por: Cabarkapa, Sonja, et al.
Publicado: (2018)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
por: Wang, Yue, et al.
Publicado: (2017)

Elevated testosterone on immunoassay in a patient with metastatic prostate cancer following androgen deprivation therapy and bilateral orchiectomy
por: Sarkar, Arjun, et al.
Publicado: (2021)

The complications of male hypogonadism: is it just a matter of low testosterone?
por: Munari, Elisabetta Veronica, et al.
Publicado: (2023)

AB37. The combination of I brachytherapy with intermittent androgen deprivation in treating locally advanced prostate cancer
por: Huang, Yi
Publicado: (2014)

Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach
por: Bonfill, Xavier, et al.
Publicado: (2018)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
por: Bang, Woo Jin, et al.
Publicado: (2022)

Non-Genomic Actions of the Androgen Receptor in Prostate Cancer
por: Leung, Jacky K., et al.
Publicado: (2017)

Androgen Deficiency and Phosphodiesterase Type 5 Expression Changes in Aging Male: Therapeutic Implications
por: Aversa, Antonio, et al.
Publicado: (2019)

Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy
por: Maru, Shintaro, et al.
Publicado: (2018)

Peripheral Arterial Tonometry to Measure the Effects of Vardenafil on Sympathetic Tone in Men with Lifelong Premature Ejaculation
por: Francomano, Davide, et al.
Publicado: (2013)

Partial Androgen Deficiency, Depression, and Testosterone Supplementation in Aging Men
por: Amore, Mario, et al.
Publicado: (2012)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Testosterone Supplementation in Patients With Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials
por: Tao, Jianping, et al.
Publicado: (2020)

A prospective study of the effect of testosterone escape on preradiotherapy prostate-specific antigen kinetics in prostate cancer patients undergoing neoadjuvant androgen deprivation therapy
por: Christie, David R.H., et al.
Publicado: (2021)

The Role of Androgen Supplementation in Women With Diminished Ovarian Reserve: Time to Randomize, Not Meta-Analyze
por: Neves, Ana Raquel, et al.
Publicado: (2021)

Baseline Testosterone Predicts Body Composition and Metabolic Response to Testosterone Therapy
por: Deepika, FNU, et al.
Publicado: (2022)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

SUN-206 Acute Cardiovascular Complications FromTestosterone Therapy
por: Shakir, Mohamed, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_58vnlfkq8eod1qb153pbdgqmgg